Preoperative radiotherapy for colorectal cancer.
In a prospective randomized trial, 700 patients with a confirmed histological diagnosis of adenocarcinoma of the rectum or rectosigmoid were randomized to receive radiotherapy prior to operation (2000 to 2500 rads in two weeks) or surgery alone. Five year observed survival in the 453 patients on whom "curative" resection was possible was 48.5% in the X-ray treated group compared with 38.8% in controls, while in the 305 having low lying lesions requiring abdominoperineal resection, survival in the treated group was 46.9% compared with 34.3% in controls. Although suggestive of a treatment benefit, neither is considered statistically significant. Histologically positive lymph nodes were found in 41.2% of the control group and in only 27.8% of the patients receiving radiotherapy. Reveiw of all patients who died during the study shows a consistently lower death rate from cancer in the radiotherapy group. Although this study suggests a treatment benefit from preoperative radiotherapy, further studies now in progress by this group and others are necessary to determine the optimal dose regimen.
D000005:Abdomen / Q000601:surgery; D001344:Autopsy; D003037:Cobalt Radioisotopes; D004219:District of Columbia; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D010502:Perineum / Q000601:surgery; D011300:Preoperative Care; D011446:Prospective Studies; D011867:Radioisotope Teletherapy; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy; D012004:Rectal Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D012811:Sigmoid Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D013997:Time Factors
D003037:Cobalt Radioisotopes